–
AEON Biopharma, Inc.
Metrics score locked — part of Premium
FY20
FY21
FY22
FY24
FY25
FY20 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY20:
FY21:
−1.49
FY22:
−35.6
FY24:
−20.3
FY25:
−17.3
Change from FY21 to FY25
millions USD
FY20:
–
FY21:
−276
FY22:
−0.31
FY24:
–
FY25:
0.00
Change from FY21 to FY25
millions USD
FY20:
–
FY21:
278
FY22:
40.5
FY24:
15.1
FY25:
20.3
millions USD
FY20:
–
FY21:
0.50
FY22:
4.62
FY24:
−5.15
FY25:
2.99
(positive)
Change from FY20 to FY25
millions USD
FY20:
−9.46
FY21:
–
FY22:
−35.9
FY24:
–
FY25:
−17.3
All amounts in millions USD FY20: figures supplemented from Twelve Data because the SEC filings do not reach back this far.